Juvenile dermatomyositis: association between nail fold capillary end row loop- area under the curve- and disease damage indicators.
Area under the curve
Disease Activity scores
Juvenile Dermatomyositis
Lipodystrophy
Nailfold vasculature
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
13 Nov 2023
13 Nov 2023
Historique:
received:
04
08
2023
accepted:
26
10
2023
medline:
15
11
2023
pubmed:
14
11
2023
entrez:
14
11
2023
Statut:
epublish
Résumé
Juvenile Dermatomyositis (JDM) is a rare autoimmune disease characterized by skin and muscle inflammation. The loss of nail fold capillary end row loops (ERL) is evidence of small vessel involvement in JDM. This study aimed to examine the specific association of ERL over the disease course with evidence of JDM disease damage. We analyzed data from 68 initially treatment-naïve JDM children who had been observed for at least five years with multiple ERL density assessments. The JDM disease course were categorized into monocyclic short, monocyclic long, polycyclic, and chronic. The ERL capillary count was cumulatively evaluated using the area under the curve (AUC) method. The mean ERL density for the treatment-naive JDM was significantly lower than that of their healthy age-matched controls (4.8 ± 1.6 /mm vs. 7.9 ± 0.9 /mm; p < 0.0001). The ERL AUC was significantly lower in children with a chronic disease course compared to those with a monocyclic short (p = 0.001) or monocyclic long disease course (p = 0.013). JDM patients with lipodystrophy had lower ERL AUC than those without lipodystrophy (p = 0.04). There was no association between ERL AUC and calcifications or fractures. Persistently decreased ERL capillary density, reflected by low ERL AUC, is associated with a chronic disease course and lipodystrophy in JDM. Despite medical therapy, the mean ERL count remained below normal even after five years, particularly in polycyclic and chronic cases. It is not clear that restoring normal capillary density is currently feasible in children with JDM.
Sections du résumé
BACKGROUND
BACKGROUND
Juvenile Dermatomyositis (JDM) is a rare autoimmune disease characterized by skin and muscle inflammation. The loss of nail fold capillary end row loops (ERL) is evidence of small vessel involvement in JDM. This study aimed to examine the specific association of ERL over the disease course with evidence of JDM disease damage.
METHODS
METHODS
We analyzed data from 68 initially treatment-naïve JDM children who had been observed for at least five years with multiple ERL density assessments. The JDM disease course were categorized into monocyclic short, monocyclic long, polycyclic, and chronic. The ERL capillary count was cumulatively evaluated using the area under the curve (AUC) method.
RESULTS
RESULTS
The mean ERL density for the treatment-naive JDM was significantly lower than that of their healthy age-matched controls (4.8 ± 1.6 /mm vs. 7.9 ± 0.9 /mm; p < 0.0001). The ERL AUC was significantly lower in children with a chronic disease course compared to those with a monocyclic short (p = 0.001) or monocyclic long disease course (p = 0.013). JDM patients with lipodystrophy had lower ERL AUC than those without lipodystrophy (p = 0.04). There was no association between ERL AUC and calcifications or fractures.
CONCLUSION
CONCLUSIONS
Persistently decreased ERL capillary density, reflected by low ERL AUC, is associated with a chronic disease course and lipodystrophy in JDM. Despite medical therapy, the mean ERL count remained below normal even after five years, particularly in polycyclic and chronic cases. It is not clear that restoring normal capillary density is currently feasible in children with JDM.
Identifiants
pubmed: 37957619
doi: 10.1186/s12969-023-00919-3
pii: 10.1186/s12969-023-00919-3
pmc: PMC10641947
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
137Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001422
Pays : United States
Commentaires et corrections
Type : UpdateOf
Informations de copyright
© 2023. The Author(s).
Références
Medicine (Baltimore). 2008 Mar;87(2):70-86
pubmed: 18344805
Pediatr Rheumatol Online J. 2017 Mar 29;15(1):18
pubmed: 28356102
Diagnostics (Basel). 2021 Dec 21;12(1):
pubmed: 35054173
Curr Treatm Opt Rheumatol. 2021 Mar;7(1):39-62
pubmed: 34354904
BMC Rheumatol. 2022 May 9;6(1):36
pubmed: 35527253
J Rheumatol. 2020 Jul 1;47(7):1011-1018
pubmed: 31371656
Nat Rev Rheumatol. 2023 Jun;19(6):343-362
pubmed: 37188756
N Engl J Med. 1975 Feb 13;292(7):344-7
pubmed: 1090839
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S118-57
pubmed: 22588740
Rheumatology (Oxford). 2018 Apr 1;57(4):671-676
pubmed: 29361142
J Microbiol Immunol Infect. 2016 Apr;49(2):264-70
pubmed: 25070283
Curr Rheumatol Rep. 2022 Jul;24(7):227-237
pubmed: 35680774
Arthritis Rheum. 2008 Feb 15;59(2):222-6
pubmed: 18240180
Biomedicines. 2023 Feb 14;11(2):
pubmed: 36831088
Pediatr Rheumatol Online J. 2023 Oct 13;21(1):118
pubmed: 37828536
J Pediatr. 2018 Apr;195:16-27
pubmed: 29576174
Int J Mol Sci. 2023 Jun 23;24(13):
pubmed: 37445728
Rheumatol Int. 2016 Jul;36(7):961-5
pubmed: 27007612
Arthritis Rheum. 2003 Feb 15;49(1):7-15
pubmed: 12579588
Arthritis Care Res (Hoboken). 2022 Jul;74(7):1065-1069
pubmed: 33290639
Arthritis Rheum. 2003 Jun 15;49(3):300-5
pubmed: 12794783
Arthritis Rheum. 2008 Feb;58(2):571-6
pubmed: 18240225
J Rheumatol. 2002 Apr;29(4):832-6
pubmed: 11950029
J Rheumatol. 2004 Aug;31(8):1644-9
pubmed: 15290747
Rheumatology (Oxford). 2011 May;50(5):885-93
pubmed: 21156669
N Engl J Med. 1975 Feb 20;292(8):403-7
pubmed: 1089199